You are using an outdated browser. Please upgrade your browser to improve your experience and security.


((Voice Over))
Welcome to the presentation titled “VYXEOS® (daunorubicin and cytarabine) Clinical Data.”

VYXEOS is indicated for the treatment of adults with newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes.

VYXEOS has different dosage recommendations than other daunorubicin and cytarabine-containing products. Do not interchange with products containing these ingredients.

Do not use in patients with a history of serious hypersensitivity reactions to cytarabine, daunorubicin or any other components of VYXEOS.

This segment is presented by Sara Tinsley, a nurse practitioner from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. She will be reviewing the phase three trial in adults for VYXEOS, the first chemotherapy approved for adults with newly-diagnosed t-AML, therapy-related acute myeloid leukemia or AML-MRC, acute myeloid leukemia with myelodysplasia-related changes.

((Sara M. Tinsley, PhD, ARNP, AOCN))

The FDA approval came from this Phase 3, multicenter, open-label trial. We were a part of that.

So, I got early experience treating patients with VYXEOS. You may know if you're a trial coordinator, it was CPX351 -- so, that was the name that it was given in the clinical trials.

You can see the study schema here. It was comparing patients in this Phase 3 trial, it was adult patients; they had to be 60 to 75 years of age; and remember, the FDA approved this for adults, and they didn't limit it to the 60 to 75 age range.

But in this study, this is what the eligibility criteria included.

They had to be previously untreated. You had to think they were able to tolerate intensive chemotherapy, and have a good performance status 0 to 2. VYXEOS is given on 1 and 3 and 5. And you can see that liposomal combination…

…is 44 milligrams to 100 miligrams per meter squared, and those come in a vial where they're together.

And then it was compared to 7 days of cytarabine and 3 days of daunorubicin, our conventional 7+3. So, that's what they were induced with.

And then, if they didn't achieve remission, they got a second induction, but the VYXEOS was given on Days 1 and 3, still the 44 milligrams per [sic] 100 milligrams per meter squared. And then, on the alternate arm, it was 5 days of cytarabine and 2 days of daunorubicin.

For consolidation, you'll note in the purple box at the top right corner, that the milligrams for VYXEOS and the number of days differs. For consolidation, which is 1 to 2 cycles, it's 29 mg/65 mg, a different combination on Days 1 and 3; and for consolidation in the other arm it was 5 days of cytarabine and 2 days of daunorubicin. And we were looking for an improvement…

…in overall survival -- that was the endpoint of the trial -- primary endpoint.

This illustrates what led to the FDA approval. This is exciting news for our patients.

The top line is the VYXEOS survival, which was 9.6 months median survival, compared with 7+3, which was 5.9 months survival.

So, that was statistically significant. When your curves separate, that's a difference; so, the VYXEOS was the winner in this case, and that's why we're here talking to you about it.

For the Kaplan-Meier estimated 1-year survival, it was 42% for the VYXEOS-treated patients, and only 28% for patients who were treated with 7+3.

This is illustrating, again, the percentage of patients who achieved CR. Purple, again, is VYXEOS, 38%, compared to 7+3, which is 26%.

And I didn't tell you the numbers -- you can see them at the bottom -- but 58/153 and 41/156.

And then the patients who were able to, rate of having a hematopoietic stem cell transplant, 34% in the VYXEOS arm, and 7+3 there was only 25%. And this could be, as many of you are aware, you have to really get a good response to your treatment to be able to proceed to transplant.

So, if you're having a better reduction and better treatment of your disease, this slide makes sense to me.

And so, the rate of hematopoietic stem cell transplant in first CR was 20% in the VYXEOS arm, and only 12% in the control arm.

Some of you may be thinking about…

…"But, wasn't this older people?" Yeah, it was 60 to 75 years of age. So, the ages for transplant keep going up and up -- you know, like, who are they taking to transplant? I just saw a general -- I think he was 78 years old -- still in wonderful health, and he wants to go to transplant.

So, at Moffitt they presented his case to see if they thought he was eligible for transplant, and the consensus was, yes, he's healthy enough to go to transplant.

So, we're trying to help him meet that goal by getting a deep response.

This is a table showing you the safety profile of VYXEOS in the Phase 3 trial.

Again, the fatal treatment-emergent, the CNS hemorrhage, we talked about that before but just to bring that point home, so that you monitor for it…

…was 2% of the patients in the VYXEOS arm, and point 7 in the control arm. And you can see the different side effects or adverse events in this table. Many of them are similar to adverse -- side effects that we see with 7+3 -- very similar.

And this is more of them. Fatigue, we all know -- that's our number one problem that patients report to us.

There was a longer time to recovery of the neutrophil count and the platelet count in the VYXEOS arm compared to 7+3…

…with prolonged thrombocytopenia and prolonged neutropenia. And you can see the median days were 49 vs. 44 for thrombocytopenia, and prolonged neutropenia at 44 vs. 35.

Now, let's look at this -- we were talking about survival -- that was the endpoint…

…the primary endpoint of the trial. The 30-day all-cause mortality was similar, well, overall mortality was higher in the 7+3, but similar in the VYXEOS and the 7+3 arm, 6% each; and the 60-day all-cause mortality you can see is clearly the 7+3 at 21% vs. 14%.

Fatal adverse events are what we see with patients with AML that are getting induction -- infection, CNS hemorrhage, and respiratory failure.

((Voice Over))
Serious or fatal hemorrhage including CNS hemorrhage have occurred with VYXEOS. Monitor blood counts regularly and provide platelet transfusions as needed.

Due to the risk of cardiotoxicity, VYXEOS is not recommended in patients with impaired cardiac function. Discontinue in patients with impaired cardiac function unless the benefit of treatment outweighs the risk. Calculate the lifetime cumulative anthracycline exposure prior to each cycle of VYXEOS.

Discontinue in patients with severe or life-threatening hypersensitivity reactions, treat the signs and symptoms and monitor until resolution.

Use only if the benefit outweighs the risks in patients with Wilson’s disease or other copper-related metabolic disorders. Discontinue in patients who develop acute copper toxicity.

Administer by the intravenous route only.

Advise females and males of the potential for VYXEOS to cause fetal harm and to use effective contraception.

The most common adverse reactions include hemorrhagic events, febrile neutropenia, rash, edema, nausea, mucositis, diarrhea, constipation, musculoskeletal pain, fatigue, abdominal pain, dyspnea, headache, cough, decreased appetite, arrhythmia, pneumonia, bacteremia, chills, sleep disorders, and vomiting.


VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).



VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information


VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.